Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10069447rdf:typepubmed:Citationlld:pubmed
pubmed-article:10069447lifeskim:mentionsumls-concept:C0025166lld:lifeskim
pubmed-article:10069447lifeskim:mentionsumls-concept:C0016263lld:lifeskim
pubmed-article:10069447lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:10069447pubmed:issue3lld:pubmed
pubmed-article:10069447pubmed:dateCreated1999-6-1lld:pubmed
pubmed-article:10069447pubmed:abstractTextA flow cytofluorometric measurement of megakaryocyte ploidy has been adapted from Tomer's method. Briefly, bone marrow is aspirated through a medium containing theophyllin, prostaglandin-E1 and other antiaggregant agents. Megakaryocytes-enriched buffy coats are recovered. Megakaryocytes are then stained for GP IIIa coupled with FITC and for DNA (propidium iodide). A Becton Dickinson FACScan flow cytometer is used for measuring the ploidy distribution of GP IIIa positive cells. The method we developed presents several advantages. Firstly, the time required is greatly decreased in comparison with other studies. Secondly, the washing steps are limited in number allowing a diminution of the cell loss. Thirdly, the method ensures a better megakaryocyte preservation. Finally, selection of megakaryocytes by ploidy and expression of GP IIIa can be made easily because of the simultaneity of the two stainings as well as by the use of a precise gating on the flow cytometer. Based on these results, we conclude that the present method provides a better means for the isolation and analysis of human normal megakaryocytes. This technique has been applied to the analysis of megakaryocyte populations from patients with abnormal platelet counts. In chronic myeloid leukemia patients, analysis of ploidy distribution shows a shift toward the low ploidy while in patients with immune thrombocytopenic purpura, polycythemia vera and essential thrombocythemia the ploidy distributions are shifted toward the high ploidy.lld:pubmed
pubmed-article:10069447pubmed:languageenglld:pubmed
pubmed-article:10069447pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10069447pubmed:citationSubsetIMlld:pubmed
pubmed-article:10069447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10069447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10069447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10069447pubmed:statusMEDLINElld:pubmed
pubmed-article:10069447pubmed:issn0017-6559lld:pubmed
pubmed-article:10069447pubmed:authorpubmed-author:ChatelainCClld:pubmed
pubmed-article:10069447pubmed:authorpubmed-author:SymannMMlld:pubmed
pubmed-article:10069447pubmed:authorpubmed-author:ChatelainBBlld:pubmed
pubmed-article:10069447pubmed:authorpubmed-author:StaquetPPlld:pubmed
pubmed-article:10069447pubmed:authorpubmed-author:BaatoutSSlld:pubmed
pubmed-article:10069447pubmed:issnTypePrintlld:pubmed
pubmed-article:10069447pubmed:volume29lld:pubmed
pubmed-article:10069447pubmed:ownerNLMlld:pubmed
pubmed-article:10069447pubmed:authorsCompleteYlld:pubmed
pubmed-article:10069447pubmed:pagination213-28lld:pubmed
pubmed-article:10069447pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:meshHeadingpubmed-meshheading:10069447...lld:pubmed
pubmed-article:10069447pubmed:year1998lld:pubmed
pubmed-article:10069447pubmed:articleTitleAnalysis of megakaryocytes by flow cytometry.lld:pubmed
pubmed-article:10069447pubmed:affiliationLaboratory of Experimental Hematology and Oncology, Oncology Unit, UCL, Brussels, Belgium.lld:pubmed
pubmed-article:10069447pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10069447pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed